JP Morgan Chase
RARX

JP Morgan Chase’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

JP Morgan Chase’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,661,842
Closed -$79.8M – 5950
2020
Q1 		$79.8M Buy
1,661,842
+737,417
+80% +$34.3M 0.02% 644
2019
Q4 		$43.4M Buy
924,425
+669,765
+263% +$29.6M 0.01% 1042
2019
Q3 		$6.02M Buy
254,660
+9,709
+4% +$288K ﹤0.01% 2537
2019
Q2 		$7.03M Buy
244,951
+5,682
+2% +$130K ﹤0.01% 2371
2019
Q1 		$5.36M Buy
239,269
+678
+0.3% +$14.6K ﹤0.01% 2534
2018
Q4 		$4.34M Sell
238,591
-75,109
-24% -$1.18M ﹤0.01% 2677
2018
Q3 		$5.67M Buy
313,700
+51,010
+19% +$605K ﹤0.01% 2645
2018
Q2 		$2.61M Sell
262,690
-173,401
-40% -$1.2M ﹤0.01% 3196
2018
Q1 		$2.31M Buy
436,091
+162,714
+60% +$1.16M ﹤0.01% 3163
2017
Q4 		$2.32M Buy
273,377
+17,077
+7% +$210K ﹤0.01% 3232
2017
Q3 		$3.74M Buy
256,300
+56,400
+28% +$853K ﹤0.01% 2770
2017
Q2 		$3.75M Buy
199,900
+50,432
+34% +$1.14M ﹤0.01% 2673
2017
Q1 		$3.18M Sell
149,468
-17,348
-10% -$332K ﹤0.01% 2743
2016
Q4 		$2.53M Buy
+166,816
New +$2.27M ﹤0.01% 2916

Other funds holding RARX

Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

JP Morgan Chase's RARX Position: Q2 2020 in Review

JP Morgan Chase sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 1,661,842 shares — an estimated $79.8M sold.

JP Morgan Chase first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $79.8M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • JP Morgan Chase reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • JP Morgan Chase sold 1,661,842 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $79.8M.
  • JP Morgan Chase first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
  • JP Morgan Chase's Ra Pharmaceuticals, Inc. Common Stock position peaked at $79.8M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on JP Morgan Chase's 13F filing for Q2 2020, filed 11 Aug 2020.